Inventiva S.A.
IVEVF
$2.28
-$1.36-37.36%
| Weiss Ratings | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.13 | |||
| Price History | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | -37.36% | |||
| 90-Day Total Return | -37.36% | |||
| Year to Date Total Return | -37.36% | |||
| 1-Year Total Return | -37.36% | |||
| 2-Year Total Return | -55.56% | |||
| 3-Year Total Return | -83.28% | |||
| 5-Year Total Return | -12.98% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.28 | |||
| 52-Week Low Price | $2.28 | |||
| 52-Week Low Price (Date) | Feb 12, 2025 | |||
| 52-Week High Price (Date) | Feb 12, 2025 | |||
| Valuation | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 273.20M | |||
| Enterprise Value | 342.90M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.25 | |||
| Earnings Per Share Growth | 11.27% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.68 | |||
| Price/Book (Q) | -1.41 | |||
| Enterprise Value/Revenue (TTM) | 13.74 | |||
| Price | $2.28 | |||
| Enterprise Value/EBITDA (TTM) | -2.72 | |||
| Enterprise Value/EBIT | -2.65 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 51.98M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 33 3 80 44 75 00 | |||
| Address | -- | |||
| Website | www.inventivapharma.com | |||
| Country | France | |||
| Year Founded | 2011 | |||
| Profitability | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -518.30% | |||
| Profit Margin | -540.26% | |||
| Management Effectiveness | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -113.05% | |||
| Return on Equity | -- | |||
| Income Statement | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 16.91M | |||
| Total Revenue (TTM) | 20.86M | |||
| Revenue Per Share | $0.40 | |||
| Gross Profit (TTM) | 19.69M | |||
| EBITDA (TTM) | -105.50M | |||
| EBIT (TTM) | -108.12M | |||
| Net Income (TTM) | -112.71M | |||
| Net Income Avl. to Common (TTM) | -112.71M | |||
| Total Revenue Growth (Q YOY) | -59.17% | |||
| Earnings Growth (Q YOY) | 12.28% | |||
| EPS Diluted (TTM) | -2.25 | |||
| EPS Diluted Growth (Q YOY) | 29.05% | |||
| Balance Sheet | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.18M | |||
| Cash Per Share (Q) | $0.22 | |||
| Total Current Assets (Q) | 30.65M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -84.71M | |||
| Current Ratio (Q) | 0.594 | |||
| Book Value Per Share (Q) | -$1.61 | |||
| Total Assets (Q) | 42.24M | |||
| Total Current Liabilities (Q) | 51.59M | |||
| Total Debt (Q) | 78.65M | |||
| Total Liabilities (Q) | 126.95M | |||
| Total Common Equity (Q) | -84.71M | |||
| Cash Flow | IVEVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 9.60M | |||
| Cash from Financing (TTM) | 58.21M | |||
| Net Change in Cash (TTM) | -22.81M | |||
| Levered Free Cash Flow (TTM) | -53.37M | |||
| Cash from Operations (TTM) | -91.64M | |||
